Meeting
2019 ASCO Annual Meeting
Final results of a phase I study evaluating INVAC-1, a novel DNA vaccine expressing an inactive form of human telomerase reverse transcriptase (hTERT) in patients with advanced solid tumors.
Authors
Luis Teixeira
Sénopôle Saint Louis, Service d’Oncologie Médicale, Hôpital Saint-Louis, APHP, Paris Diderot University, Paris, France
Luis Teixeira , Jacques Medioni , Ludovic Doucet , Antoine Angelergues , Stephane Culine , Stephane Oudard , Mara Brizard , Zineb Ghrieb , Olivier Adotevi , Caroline Laheurte , Marie-Agnès Dragon Durey , Pierre Laurent-Puig , Jean-Jacques Kiladjian , Simon wain-Hobson , Valérie Doppler , Rémy DeFrance , Julie Garibal , Thierry Huet , Pierre Langlade Demoyen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT02301754
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2642)
DOI
10.1200/JCO.2019.37.15_suppl.2642
Abstract #
2642
Poster Bd #
286
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Pancreatic and esophageal cancer cohorts.
First Author: Susanna Varkey Ulahannan
Poster
2017 ASCO Annual Meeting
Results of a first-in-human phase I study of INVAC-1, an optimized plasmid DNA encoding an inactive form of human telomerase reverse transcriptase (hTERT), in patients with advanced solid tumors.
First Author: Luis Teixeira
Poster
2024 ASCO Annual Meeting
A phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors.
First Author: Toshihiko Doi
Poster
2022 ASCO Annual Meeting
A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors.
First Author: Kevin Joseph Harrington